MEDAMI 2022 - Multimodality molecular neuro-imaging: clinical and technical state-of-the-art

Session

Introduction / degeneration / addiction / trauma

Session 1

5 Sept 2022, 08:30

Conveners

Introduction / degeneration / addiction / trauma

• Peter Krizan

1. Introduction

Vesna Sossi (University of British Columbia)

05/09/2022, 08:30

Degeneration, Addiction And Trauma

Invited

14. Multimodality in the context of understanding of brain function in psychiatry/addiction

Ilan Rabiner (King's College London)

05/09/2022, 08:40

Degeneration, Addiction And Trauma

Invited

17. X-Ray Darkfield Imaging - Basic Physics & First Clinical Results for COVID-19

Franz Pfeiffer (Technical University of Munich)

05/09/2022, 09:10

Degeneration, Addiction And Trauma

Invited

3. Biomarkers for Neurodegeneration with a focus on Alzheimer’s and Parkinson’s Disease

Gunn Roger (Imperial College London)

05/09/2022, 09:40

Tracers and other modalities

Invited

Alzheimer's and Parkinson's disease represent two of the most prevalent neurodegenerative diseases with dramatic socio-economic impacts for governments and healthcare systems to address. Currently, excepting the modest effects of Aducanumab in AD, there are no disease modifying therapies for either disease. However, the development of future disease modifying drugs represents a tremendously...